RA PHARMCTL INC Company Profile (NASDAQ:RARX)

About RA PHARMCTL INC (NASDAQ:RARX)

RA PHARMCTL INC logoRa Pharmaceuticals, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade. It has leveraged the Extreme Diversity peptide chemistry platform to develop a portfolio of products that selectively inhibit the complement system and other immune targets. Its main program, RA101495, is a macrocyclic peptide inhibitor of complement component 5 (C5), which is in Phase I stage of development for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). RA101495 binds a site on the C5 protein to inhibit cleavage into C5a and C5b, thereby preventing red blood cell lysis by inhibiting the production and assembly of the membrane attack complex (MAC). RA101495 is being developed as an alternative to eculizumab therapy for patients with PNH.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:RARX
  • CUSIP: N/A
  • Web: www.rapharma.com
Capitalization:
  • Market Cap: $341.62 million
  • Outstanding Shares: 22,609,000
Average Prices:
  • 50 Day Moving Avg: $15.50
  • 200 Day Moving Avg: $20.28
  • 52 Week Range: $12.05 - $27.84
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.26
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $4.26 per share
  • Price / Book: 3.55
Profitability:
  • EBIDTA: ($42,070,000.00)
  • Return on Equity: -64.75%
  • Return on Assets: -44.33%
Debt:
  • Current Ratio: 13.98%
  • Quick Ratio: 13.98%
Misc:
  • Average Volume: 173,908 shs.
  • Short Ratio: 6.46
 

Frequently Asked Questions for RA PHARMCTL INC (NASDAQ:RARX)

What is RA PHARMCTL INC's stock symbol?

RA PHARMCTL INC trades on the NASDAQ under the ticker symbol "RARX."

How were RA PHARMCTL INC's earnings last quarter?

RA PHARMCTL INC (NASDAQ:RARX) issued its earnings results on Wednesday, August, 9th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.50) by $0.07. View RA PHARMCTL INC's Earnings History.

When will RA PHARMCTL INC make its next earnings announcement?

RA PHARMCTL INC is scheduled to release their next quarterly earnings announcement on Tuesday, December, 5th 2017. View Earnings Estimates for RA PHARMCTL INC.

Where is RA PHARMCTL INC's stock going? Where will RA PHARMCTL INC's stock price be in 2017?

4 equities research analysts have issued twelve-month target prices for RA PHARMCTL INC's shares. Their forecasts range from $19.00 to $32.00. On average, they expect RA PHARMCTL INC's share price to reach $26.75 in the next twelve months. View Analyst Ratings for RA PHARMCTL INC.

Who are some of RA PHARMCTL INC's key competitors?

Who are RA PHARMCTL INC's key executives?

RA PHARMCTL INC's management team includes the folowing people:

  • Douglas A. Treco Ph.D., President, Chief Executive Officer, Co-Founder, Director
  • Jeffrey Johnston M.D., Senior Vice President, Chief Medical Officer
  • Alonso Ricardo Ph.D., Senior Vice President of Research & Development
  • Kerry Black, Executive Director, Operations
  • Edward T. Mathers, Board Member

When did RA PHARMCTL INC IPO?

(RARX) raised $75 million in an initial public offering (IPO) on Wednesday, October 26th 2016. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Credit Suisse, Jefferies and BMO Capital Markets served as the underwriters for the IPO and SunTrust Robinson Humphrey was co-manager.

Who owns RA PHARMCTL INC stock?

RA PHARMCTL INC's stock is owned by a number of of institutional and retail investors. Top institutional investors include NEA Management Company LLC (15.48%), RA Capital Management LLC (5.98%), VHCP Management II LLC (3.41%), Tekla Capital Management LLC (1.75%), Vanguard Group Inc. (1.54%) and JPMorgan Chase & Co. (0.89%). Company insiders that own RA PHARMCTL INC stock include Bioventures Ltd Novartis, Harry R Weller and Rajeev M Shah. View Institutional Ownership Trends for RA PHARMCTL INC.

Who sold RA PHARMCTL INC stock? Who is selling RA PHARMCTL INC stock?

RA PHARMCTL INC's stock was sold by a variety of institutional investors in the last quarter, including Sectoral Asset Management Inc, Emory University, Ameriprise Financial Inc. and Wells Fargo & Company MN. View Insider Buying and Selling for RA PHARMCTL INC.

Who bought RA PHARMCTL INC stock? Who is buying RA PHARMCTL INC stock?

RA PHARMCTL INC's stock was acquired by a variety of institutional investors in the last quarter, including Tekla Capital Management LLC, Numeric Investors LLC, Nexthera Capital LP, Candriam Luxembourg S.C.A., Vanguard Group Inc., OxFORD Asset Management LLP, Northern Trust Corp and JPMorgan Chase & Co.. Company insiders that have bought RA PHARMCTL INC stock in the last two years include Harry R Weller and Rajeev M Shah. View Insider Buying and Selling for RA PHARMCTL INC.

How do I buy RA PHARMCTL INC stock?

Shares of RA PHARMCTL INC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is RA PHARMCTL INC's stock price today?

One share of RA PHARMCTL INC stock can currently be purchased for approximately $15.11.


MarketBeat Community Rating for RA PHARMCTL INC (NASDAQ RARX)
Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  57 (Vote Outperform)
Underperform Votes:  48 (Vote Underperform)
Total Votes:  105
MarketBeat's community ratings are surveys of what our community members think about RA PHARMCTL INC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for RA PHARMCTL INC (NASDAQ:RARX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $26.75 (77.04% upside)

Analysts' Ratings History for RA PHARMCTL INC (NASDAQ:RARX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/14/2017Jefferies Group LLCReiterated RatingBuy$25.00LowView Rating Details
4/18/2017Credit Suisse GroupReiterated RatingOutperform$19.00LowView Rating Details
3/7/2017BMO Capital MarketsBoost Price TargetPositive$24.00 -> $31.00N/AView Rating Details
11/21/2016SunTrust Banks, Inc.Initiated CoverageBuy$32.00N/AView Rating Details
(Data available from 8/20/2015 forward)

Earnings

Earnings History for RA PHARMCTL INC (NASDAQ:RARX)
Earnings by Quarter for RA PHARMCTL INC (NASDAQ:RARX)
Earnings History by Quarter for RA PHARMCTL INC (NASDAQ RARX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
12/5/2017        
8/9/2017Q2 2017($0.50)($0.56)ViewN/AView Earnings Details
5/11/2017Q1 2017($0.58)($0.50)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for RA PHARMCTL INC (NASDAQ:RARX)
2017 EPS Consensus Estimate: ($2.56)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.59)($0.50)($0.55)
Q2 20172($0.61)($0.57)($0.59)
Q3 20172($0.74)($0.61)($0.68)
Q4 20172($0.82)($0.67)($0.75)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for RA PHARMCTL INC (NASDAQ:RARX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for RA PHARMCTL INC (NASDAQ:RARX)
Insider Ownership Percentage: 14.50%
Institutional Ownership Percentage: 61.77%
Insider Trades by Quarter for RA PHARMCTL INC (NASDAQ:RARX)
Institutional Ownership by Quarter for RA PHARMCTL INC (NASDAQ:RARX)
Insider Trades by Quarter for RA PHARMCTL INC (NASDAQ:RARX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/19/2017Bioventures Ltd NovartisMajor ShareholderSell56,420$21.29$1,201,181.80View SEC Filing  
6/7/2017Bioventures Ltd NovartisMajor ShareholderSell12,114$22.63$274,139.82View SEC Filing  
6/5/2017Bioventures Ltd NovartisMajor ShareholderSell19,647$23.38$459,346.86View SEC Filing  
6/1/2017Bioventures Ltd NovartisMajor ShareholderSell46,261$23.93$1,107,025.73View SEC Filing  
5/26/2017Bioventures Ltd NovartisMajor ShareholderSell5,353$25.14$134,574.42View SEC Filing  
5/24/2017Bioventures Ltd NovartisMajor ShareholderSell17,451$25.01$436,449.51View SEC Filing  
5/18/2017Bioventures Ltd NovartisMajor ShareholderSell9,019$25.50$229,984.50View SEC Filing  
5/17/2017Bioventures Ltd NovartisMajor ShareholderSell42,615$25.90$1,103,728.50View SEC Filing  
10/31/2016Harry R WellerMajor ShareholderBuy338,462$13.00$4,400,006.00View SEC Filing  
10/31/2016Rajeev M ShahDirectorBuy161,538$13.00$2,099,994.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for RA PHARMCTL INC (NASDAQ:RARX)
Latest Headlines for RA PHARMCTL INC (NASDAQ:RARX)
Source:
DateHeadline
americanbankingnews.com logoZacks: Analysts Expect Ra Pharmctl Inc (RARX) Will Post Earnings of -$0.74 Per Share
www.americanbankingnews.com - August 19 at 12:30 AM
americanbankingnews.com logoQ3 2017 Earnings Estimate for Ra Pharmctl Inc Issued By SunTrust Banks (NASDAQ:RARX)
www.americanbankingnews.com - August 14 at 2:28 AM
americanbankingnews.com logoRa Pharmctl Inc (RARX) Releases Quarterly Earnings Results, Misses Expectations By $0.06 EPS
www.americanbankingnews.com - August 11 at 12:40 AM
finance.yahoo.com logoRa Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - August 10 at 7:17 AM
finance.yahoo.com logoRa Pharmaceuticals Receives Orphan Drug Designation from the U.S. FDA for RA101495 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria
finance.yahoo.com - August 1 at 5:19 AM
americanbankingnews.com logo Analysts Expect Ra Pharmctl Inc (NASDAQ:RARX) to Announce -$0.57 Earnings Per Share
www.americanbankingnews.com - July 31 at 6:30 PM
americanbankingnews.com logoZacks: Ra Pharmctl Inc (RARX) Given Consensus Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - July 21 at 8:22 PM
finance.yahoo.com logoRa Pharmaceuticals Announces Publication of Positive Preclinical Data with RA101295 for the Treatment of Escherichia Coli Sepsis
finance.yahoo.com - July 20 at 7:06 AM
americanbankingnews.com logoJefferies Group LLC Reiterates Buy Rating for Ra Pharmctl Inc (RARX)
www.americanbankingnews.com - July 14 at 10:24 PM
businesswire.com logoNightstar Appoints David Lubner to its Board of Directors
www.businesswire.com - July 14 at 7:48 AM
americanbankingnews.com logoZacks: Analysts Anticipate Ra Pharmctl Inc (NASDAQ:RARX) Will Post Earnings of -$0.57 Per Share
www.americanbankingnews.com - July 7 at 12:24 PM
americanbankingnews.com logoRa Pharmctl Inc (RARX) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - June 29 at 7:30 AM
finance.yahoo.com logoHere's Why Ra Pharmaceuticals Inc. Tumbled as Much as 32% Today
finance.yahoo.com - June 27 at 7:32 PM
finance.yahoo.com logoRa Pharmaceuticals Announces Initial Data from Phase 2 Clinical Trial of RA101495 in PNH
finance.yahoo.com - June 27 at 7:43 AM
finance.yahoo.com logoRa Pharmaceuticals Presents Data on Oral Small Molecule Complement Inhibitors at the 22nd Congress of the European Hematology Association
finance.yahoo.com - June 24 at 8:03 PM
finance.yahoo.com logoRa Pharmaceuticals to Host Conference Call on Initial Phase 2 Data for RA101495 in PNH
finance.yahoo.com - June 22 at 9:44 AM
americanbankingnews.com logo RA PHARMCTL INC (RARX) Given Consensus Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - June 21 at 7:50 AM
americanbankingnews.com logoRa Pharmctl Inc (RARX) Major Shareholder Sells $1,201,181.80 in Stock
www.americanbankingnews.com - June 20 at 7:37 PM
americanbankingnews.com logoRa Pharmctl Inc (RARX) Sees Large Decrease in Short Interest
www.americanbankingnews.com - June 14 at 7:14 AM
americanbankingnews.com logoZacks: Analysts Expect Ra Pharmctl Inc (RARX) Will Post Earnings of -$0.57 Per Share
www.americanbankingnews.com - June 13 at 2:50 PM
americanbankingnews.com logoInsider Selling: Ra Pharmaceuticals Inc (RARX) Major Shareholder Sells 12,114 Shares of Stock
www.americanbankingnews.com - June 8 at 7:28 PM
finance.yahoo.com logoRa Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : RARX-US : June 6, 2017
finance.yahoo.com - June 6 at 8:54 PM
americanbankingnews.com logoBioventures Ltd Novartis Sells 19,647 Shares of Ra Pharmaceuticals Inc (RARX) Stock
www.americanbankingnews.com - June 6 at 7:51 PM
americanbankingnews.com logoBioventures Ltd Novartis Sells 46,261 Shares of Ra Pharmaceuticals Inc (RARX) Stock
www.americanbankingnews.com - June 2 at 7:43 PM
finance.yahoo.com logoRa Pharmaceuticals to Present at the Jefferies 2017 Global Healthcare Conference
finance.yahoo.com - May 31 at 12:54 PM
americanbankingnews.com logo Ra Pharmaceuticals Inc (RARX) Given Consensus Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - May 30 at 8:14 PM
americanbankingnews.com logoRa Pharmaceuticals Inc (RARX) Major Shareholder Sells $134,574.42 in Stock
www.americanbankingnews.com - May 30 at 8:07 PM
americanbankingnews.com logoRa Pharmaceuticals Inc (RARX) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - May 27 at 1:58 PM
americanbankingnews.com logoZacks Investment Research Upgrades Ra Pharmaceuticals Inc (RARX) to Buy
www.americanbankingnews.com - May 27 at 7:32 AM
americanbankingnews.com logoRa Pharmaceuticals Inc (RARX) Major Shareholder Bioventures Ltd Novartis Sells 17,451 Shares
www.americanbankingnews.com - May 25 at 7:42 PM
americanbankingnews.com logoInsider Selling: Ra Pharmaceuticals Inc (RARX) Major Shareholder Sells 9,019 Shares of Stock
www.americanbankingnews.com - May 22 at 7:47 PM
americanbankingnews.com logoInsider Selling: Ra Pharmaceuticals Inc (RARX) Major Shareholder Sells 42,615 Shares of Stock
www.americanbankingnews.com - May 18 at 7:26 PM
finance.yahoo.com logoRa Pharmaceuticals to Present at the 22nd Congress of the European Hematology Association
finance.yahoo.com - May 18 at 9:28 AM
americanbankingnews.com logoRa Pharmaceuticals Inc (RARX) Upgraded at Zacks Investment Research
www.americanbankingnews.com - May 17 at 7:48 AM
americanbankingnews.com logo Analysts Expect Ra Pharmaceuticals Inc (RARX) Will Announce Earnings of -$0.57 Per Share
www.americanbankingnews.com - May 16 at 8:14 PM
finance.yahoo.com logoRa Pharmaceuticals to Present at the UBS 2017 Global Healthcare Conference
finance.yahoo.com - May 16 at 9:39 AM
finance.yahoo.com logoRa Pharmaceuticals, Inc. – Value Analysis (NASDAQ:RARX) : May 15, 2017
finance.yahoo.com - May 15 at 6:40 PM
finance.yahoo.com logoRa Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : RARX-US : May 12, 2017
finance.yahoo.com - May 12 at 8:15 PM
americanbankingnews.com logoRa Pharmaceuticals Inc (RARX) Issues Earnings Results, Beats Expectations By $0.08 EPS
www.americanbankingnews.com - May 12 at 12:14 PM
finance.yahoo.com logoRa Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - May 11 at 7:55 PM
americanbankingnews.com logoZacks: Ra Pharmaceuticals Inc (RARX) Given $27.67 Consensus Price Target by Analysts
www.americanbankingnews.com - May 5 at 12:36 PM
americanbankingnews.com logoRa Pharmaceuticals Inc (RARX) Stock Rating Reaffirmed by Jefferies Group LLC
www.americanbankingnews.com - April 26 at 6:24 PM
finance.yahoo.com logoRa Pharmaceuticals Initiates Dosing of RA101495 in PNH Patients
finance.yahoo.com - April 26 at 5:51 PM
finance.yahoo.com logoETFs with exposure to Ra Pharmaceuticals, Inc. : April 26, 2017
finance.yahoo.com - April 26 at 5:51 PM
americanbankingnews.com logo Analysts Anticipate Ra Pharmaceuticals Inc (RARX) Will Post Earnings of -$0.55 Per Share
www.americanbankingnews.com - April 26 at 8:19 AM
americanbankingnews.com logoRa Pharmaceuticals Inc (RARX) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - April 23 at 8:38 AM
americanbankingnews.com logoRa Pharmaceuticals Inc (RARX) Receives Outperform Rating from Credit Suisse Group AG
www.americanbankingnews.com - April 18 at 2:06 PM
americanbankingnews.com logo Analysts Set $27.67 Price Target for Ra Pharmaceuticals Inc (RARX)
www.americanbankingnews.com - April 17 at 11:32 AM
americanbankingnews.com logoRa Pharmaceuticals Inc's Lock-Up Period Will End on April 24th (NASDAQ:RARX)
www.americanbankingnews.com - April 17 at 9:42 AM
americanbankingnews.com logoRa Pharmaceuticals Inc (RARX) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - April 12 at 7:29 AM

Social

Chart

RA PHARMCTL INC (RARX) Chart for Sunday, August, 20, 2017

This page was last updated on 8/20/2017 by MarketBeat.com Staff